The Determinants of Pricing in Pharmaceuticals:
Are U.S. prices really higher than those of Canada?[*]

Antonio Cabrales[†]   Sergi Jiménez-Martín[‡]

version: April 2007
printing date: April 26, 2007

Abstract

This paper studies price determination in pharmaceutical markets using data for 25 countries, five years and a comprehensive list of products from the MIDAS IMS database. We show that market power and the quality of the product has a significantly positive impact of prices. The nationality of the producer appears to have a small and often insignificant impact on prices, which suggests that countries which regulates prices have relatively little power to do it in a way that advances narrow national interest. We produce a theoretical explanation for this phenomenon based on the fact that low negotiated prices in a country would have a knock-on effect in other markets, and is thus strongly resisted by producers. Another key finding is that the U.S. has prices that are not significantly higher than those of countries with similar income levels. This, together with the former observation on the effect of the nationality of producers casts doubt on the ability of countries to pursue "free-riding" regulation.

Keywords: Pharmaceutical prices.
JEL Classification: I10, I18, L18, L65

[†]Departamento de Economa, Universidad Carlos III de Madrid, Madrid 126, 28903 Getafe, Spain. Email: antonio.cabrales@uc3m.es

[‡]IAE-CSIC and Departament d'Economia i Empresa, Universitat Pompeu Fabra, Ramon Trias Fargas 25-27, 08005 Barcelona, Spain. Email: sergi.jimenez@upf.edu

1 Introduction

There are serious theoretical reasons for the existence of non-market interventions in the pharmaceutical industry. The presence of substantial R&D and marketing (sunk) costs creates large barriers to entry, which limits the positive effects of competition. In addition, the consumer is typically insured, so she does not pay the full cost of the medicine. Furthermore, consumption often requires a prescription, and the prescribing physician is, in most cases, insulated from the economic aspects of the decision. This situation creates severe informational and incentive problems, which make some kind of government regulation (or insurance company control) potentially beneficial in theory. Indeed, Ballance et al. (1992) survey 56 nations and find that most countries impose some form of price controls. But the amount of regulation varies a great deal across countries, as they go from "substantial," to "limited," to "nonexistent." Even the form of regulation can be heterogeneous. As Scherer (2000) notes, the instruments can be: reference pricing, product per product negotiation, price caps, rate of return regulation and formula pricing.

The existence of theoretical reasons for price intervention does not imply that actual regulation is necessarily efficient. It may also exist to transfer rents from some groups of economic agents to others. A firm, which spends vast amounts of money to develop a new drug, necessarily has to expect large operating profits, after the discovery has been made. But at that time, it may be in the (short-term) interest of a government to impose low prices for the product in order to receive the goodwill of the consumers/voters. This problem becomes more acute if the owners of the companies are mainly located in countries different from those where the products are sold.[1] The government when taking their decision will most likely consider the welfare of their voters.[2]

Thus, the question of what determines actual regulation, rent-seeking or economic efficiency, deserves an empirical investigation. In addition, of course, the prices of pharmaceuticals depend on other economic factors, such as the usefulness of the products or the market power of the producers, in different degrees. In spite of this interest, there has been no systematic empirical study of the determinants of pricing in this industry for a large set of products and countries.[3] In this paper we attempt to fill this vacuum. We study pricing in pharmaceuticals using a multicountry and multiproduct data set from the IMS MIDAS international dataset for the period 1998-2003. Our dataset encompasses a large number of countries including the top ten in

---

[1] Table 11b in Gambardella, Orsenigo and Pammolli (2000), for example shows the location of headquarters (which have a strong correlation with main ownership nationality) of top 20 pharmaceutical corporation and their markets.

[2] Notice that among the top 20 pharmaceutical firms only one is French, and none is Japanese or Italian. Perhaps it will not come as a surprise, then, that those three countries are more heavily regulated; whereas Germany, and, specially, the UK and the USA, with many more firms in the top 20 list, are less heavily regulated or have relatively free pricing (see Danzon and Chao 2000a).

[3] The existing studies mostly look at small groups of chemicals for a few countries (Lu and Comanor 1998, Danzon and Chao 2000a, 2000b Ekelund and Persson 2003).

terms of pharmaceutical expenditures, as well as other countries that are either smaller in size or with a lower income. The data comprises products from a large number of groups or anatomic classifications. The richness of the data allow us to study the determinant of price variation between countries, and we give special attention to both regulatory regimes and industrial structure.

Literature The work of Danzon and Chao (2000a, 2000b) is specially relevant for our purposes within the large literature on this topic. They study the effect of regulatory regimes on price setting. Their data includes seven big countries in terms of spending which are classified in terms of the severity of regulation.[4] Danzon and Chao (2000a) estimate a reduced form equation where prices depend on quality attributes of the product and on the competition characteristics of the market. Their empirical results suggest that regulation limits the beneficial effect of competition. Using similar data, Danzon and Chao (2000b) demonstrate that the conventional view that drug prices are much higher in the US than in other countries is incorrect. The biased perception is due to the small, unrepresentative samples and to the inappropriate methods used in prior studies. In this paper we further confirm and amplify this view by showing, with a much larger database and a robust empirical strategy, that the U.S. prices are indeed in line with those of countries of similar income levels. In a similar vein, a study by the U.S. Department of Commerce (2004) has argued that the lower (income-adjusted) prices induced by regulation in the OECD countries, with respect to the U.S., hurts consumers in the long term through the lower incentive for R&D and thus through lower discovery of life-saving drugs. Domínguez, Ganuza and Llobet (2006) provide a theoretical counterargument. Price controls hurt small ("me-too") innovations more than the relatively price inelastic drastic innovations, and could even induce larger investment by focusing firms on the drastic innovations. We have a more fundamental challenge to the U.S. Department of Commerce (2004) results, since our more carefully income-adjusted prices do not show that U.S. prices are indeed lower, in line with the results of Danzon and Chao for a smaller database.

Kyle (2005) examines the effect of price controls in the extent and timing of the launch of new

---

[4]From more to less regulated, the first group includes Italy, France and Japan were launch prices are regulated and afterward are revised downwards over the drug's life cycle. The price of new varieties is related to the price of established varieties. In addition, consumer and physicians demand are expected to be inelastic due to insurance coverage, and generics substitution by pharmacists was not allowed in France and Italy at the time of the study. Moreover, pharmacies are paid a margin on the product price which may encourage the sale of more expensive products. The second group includes UK and Germany were corporations are free to set prices at launch but prices cannot increase (freely) later on. In addition, in both countries there is some type of upper bound to prices, implemented either through a reference price (Germany) or a maximum overall rate of return (UK). Generics substitution by pharmacists is the main source of price-demand elasticity, since they keep the margin between the reimbursement price and the manufacturers price. This is possible in UK, and to a lesser extent in Germany. The third group includes US and Canada where prices are free, consumers' and physicians' demands appear to be less inelastic and generic substitution on the side of the pharmacists is encouraged as a means to promote competition.

drugs around the world and finds that regulation has a statistically and quantitatively important effect on pharmaceutical launches. The effect takes two forms. First, drugs invented by firms headquartered in countries that use price controls reach fewer markets and with longer delays than products that originate in countries without price controls. Second, companies delay launch into price-controlled markets, and are less likely to introduce their products in additional markets after entering a country with low prices. Launches into low price countries in Europe are further delayed after a regulatory change allowing parallel imports, which could potentially depress prices in high price markets. The findings of Kyle (2005) support our theoretical explanation for our own finding that the effect of the nationality of the producers on prices is negligible. We argue theoretically that the fear of reducing prices in markets with high prices leads producers to a strategically credible resistance to price reduction in more regulated countries.

In terms of empirical specification, previous evidence in this industry suggest that marginal costs are almost irrelevant in the industry and recommend the use of a hedonic price approach. For example, Berndt et al (1999) estimate a hedonic price equation that measures the price impact of drug attributes. Likewise, we do not attempt to estimate marginal cost effects on prices.

The effect of entry of generic products on price evolution has attracted recently a lot of attention. The empirical evidence on this issue is ambiguous. Some authors (Grabowski and Vernon, 1992 and 1997, and Caves, Whinston and Hurwitz 1991) report that brand-name prices increased after the entry of generic competition, while others (Wiggins and Maness, 1994) find a reduction in brand-name prices following entry. Finally, Frank and Salkever (1992 and 1997) report that brand name prices increased while generic products prices fell, producing a reduction in average prices. Our analysis shows that generics prices are indeed lower than those of brand name products, and we also show (see section 5.3), that the impact of the number of competitors depends on the therapeutical class analyzed (thus explaining the diverging results of earlier literature).

Empirical strategy and results Our empirical strategy introduces several innovations with respect to the previous empirical literature in the subject.

1. We estimate pricing equations separately for each country, and then we obtain estimates by pooling the countries. By pooling the sample we will be able to explore the interplay of cross-national variables and regulation in price setting. For example, by including as an explanatory variable the GDP per capita, or the ratio of public spending to GDP, we can assess, in a very disaggregate context, whether higher prices are observed primarily in richer countries or in countries with larger public sectors.[5]

---

[5]Danzon and Furukawa (2003) suggest theoretically that fixed costs should be distributed across countries depending on demand elasticities, so that higher prices should be observed in richer countries. This suggests that in a multi-country study, like ours, variables with cross-country variation should be included in the regression.

2. We exploit the panel nature of the data and control for unobserved heterogeneity at the product level. By doing so, we control for time invariant factors that affect price setting. In particular we control for "unobserved´´ marginal effects. However, this comes at a cost, since this reduces notably the variation of the data. In this context, we identify the effect of time-invariant variables by following a two-stage procedure.

3. With the exception of products without consumption or information in a given period, we do not restrict the sample in any way. However, we do explore the sensitivity of our results to the restriction of the sample in several dimensions:

    (a) The restriction to single molecule products, which has been explored in other studies.[6]

    (b) The variation of the sample to the number of countries where a corporation is present.

    (c) The variation of the sample to the number of countries a molecule is present.

    (d) The analysis by therapeutical category.

    By exploring these dimensions we are able to assess the robustness of the results to the restriction of the sample, as well as the effects of increasing the "internationality" of the corporations analyzed and the "diffusion" of molecules.

Our results show that variables related to the quality of the product are strongly significant in explaining the prices. For example, older products are less expensive, and recently approved ones command a price premium. This is reassuring, as it represent a check that pricing has an element of rationality, but possibly it is not very surprising. There is also robust evidence in the data that market forces operate in the expected way. This can be seen in the fact in that larger firms (measured in different ways) tend to command higher prices, although not strongly in quantitative terms. Also, generic products, which operate in off-patent markets (thus, probably more competitive ones) have lower prices.

Another sensible finding is that higher per-capita income produces higher prices in any given country, most likely derived from a lower price elasticity, confirming Danzon and Furukawa (2003) theoretical observation.[7] There is also a positive effect on prices of a higher ratio of public expenditure to GDP. The interpretation of this finding is less straightforward. Most likely, a higher public expenditure to GDP also signals a low price elasticity, relative to countries with the same income, probably derived from higher insulation of consumers from prices through national health insurance. However, the size of this effect depends on the level of regulation, and it is larger for less regulated countries.

---

[6] For example, Danzon and Chao (2000a).

[7] "the global joint costs should be recouped through price markups over marginal cost that differ based on income levels, assuming that income is a major determinant of "true" price elasticity. Thus, price differentials that are related to income would be consistent with both economic efficiency and equity." Danzon and Furukawa (2003, p. 534).

To understand the impact of regulation we classified the countries in our sample in three groups, from less to more regulated.[8] We observe that the country fixed effect of more regulated countries tends, indeed, to be lower than that of the rest, although this is far from universal, and substantial variation remains. It is, thus, interesting to note that prices do not necessarily conform with the conventional wisdom about countries regulatory habits and regimes. As it turns out, the fixed effect of the U.S.A. is significantly higher than that, of Canada (but not for all specifications), France or Italy. This means that if average prices in the U.S.A. are higher it is not because other countries engage in "free riding regulation," but because its per-capita income is higher. And in fact, in many cases, the U.S.A. pays less, not more, than countries of similar income or lower income (such as Eastern European countries).[9] Our interpretation is that its larger, more competitive, market provides with some protection with respect to similarly rich countries.

The rest of the paper is structured as follows. We first present in section 2 a model which accounts for the empirical findings we discuss in later sections. Then, in section 3, we present the empirical strategy. Section 4 explains the data and the construction of the variables employed. Section 5 presents the main results from the analysis. Finally, section 6 concludes.

2   The model

We assume demand for a pharmaceutical product to be iso-elastic, so as to estimate a log-linear specification. In other words, we can write it:

$$Q = \exp[A(P^c, v, S)]p_Q^{-\beta}$$

implying

$$\ln Q = A(P^c, v, S) - \beta \ln p_Q.$$

The function $A(P^c, v, s)$ subsumes all the factors affecting demand which do not come from the own price of the good. The main ones, as the notation makes clear, and which we use in the estimation, come from direct or indirect substitutes (P^c), the quality of the product (v, innovativeness, perceived quality) or size of the market (S).

We have stressed in the introduction one aspect of the pricing problem which we think is of paramount importance. Namely, we are interested in how the price varies across countries. There are strategic complications that arise from the fact that in this market, the usual competitive assumptions tend to be wrong. Some government regulate heavily the prices of pharmaceutical, and others do not. Even the countries who do not regulate markets are affected by others' regulations, as current media controversies in the U.S. regarding prices abroad reflect. This implies that the national differences in price behavior could be large, as we will see in the

---

[8]See section 4 for an explanation of the classification method.

[9]This implies that we partially confirm (and extend to a much larger and varied set of countries) the findings in Danzon and Chao (200b)

estimation, and may come from unexpected sources. In order to clarify some of the issues at stake, let us present a simplified political economy model that captures some interesting facets of the problem.

Assume that a pharmaceutical company sells monopolistically in two countries a product which it produces at constant marginal cost c (the monopoly may occur because it holds a valid patent). Demands at the Home (H) and Foreign (F) countries are log-linear (as in the model we estimate):

$$\ln Q_H = A_H - b \ln p_H; \ \ln Q_F = A_F - b \ln p_F$$

The prices are determined through a game, which is intended to capture an important fact of real-life markets. Namely, many of the producing countries are large, rich, or both (the U.S., the U.K., Switzerland). Many of the countries doing strict price regulation have negligible industries. If governments regulate with an eye on the welfare of their own country, they would perhaps tend to be harsh on the foreign companies. As we will see in the data, though, that is not the case. Our model will produce both the tendency for harsh regulation as well as an endogenous protective circumstance. This protection comes from the fact that, either by arbitrage, or by policy (governmental or from large purchasers, such as HMOs), the prices abroad affect the prices at home. So firms from unregulated countries which accept low prices abroad, can suffer at home (which, remember, may be a large market). And they could refuse to sell at all, if the foreign government demands too low a price. Knowing which, of course, the foreign government will set the minimum price consistent with participation of the foreign company.

More formally, let the government of the H country pursue a price-control policy. It unilaterally sets the maximum price at which the company can sell the product in country H, $\overline{p}_H$. The firm can choose between selling in that country, in which case it must choose a price $p_H \leq \overline{p}_H$ or not to sell the good at all. In the F country the regulation is of the reference price type, that is, $p_F \leq p_H$. With isoelastic prices, the monopolistic price is equal in both countries. This means that the *reference price constraint* is always binding, and $p_F = p_H$ provided the good is sold in both countries and that the price set in F is lower than its monopoly price.[10]

If the company has headquarters in the H country, the regulator sets the price to maximize consumer surplus at H, plus firms profits. Since the prices set in this way are never higher than those preferred by the monopolist, the price constraint of the government will always be binding. Thus, the price in country H is completely determined by the regulator, by solving the following program:

$$\max_{p} A_H \frac{p^{1-\beta}}{\beta - 1} + \left(A_H p^{-\beta} + A_F p^{-\beta} \right)(p - c)$$

$$\text{subject to } \left(A_H p^{-\beta} + A_F p^{-\beta} \right)(p - c) \geq \pi_F^*$$

---

[10] An alternative modeling choice, with similar implications, would be to think that pharmaceutical imports are legal, and then arbitrage would force a single price in both countries.

where π_F^* is the monopoly profit of selling only at F, in which case it is sold at monopoly prices, and is given by

$$\pi_F^* = A_F \left(\frac{\beta c}{\beta - 1} \right)^{-\beta} \left(\frac{\beta c}{\beta - 1} - c \right)$$

. We solve the problem both with and without the constraint and then show when is the constraint binding at the optimum. The price p that solves the problem without the constraint is

$$p^* = \frac{\beta \left(A_F + A_H \right) c}{(\beta - 1) \left(A_F + A_H \right) + A_H}$$

The price p^* satisfies the constraint if:

$$(A_H + A_F) \left(\frac{\beta \left(A_F + A_H \right) c}{(\beta - 1) \left(A_F + A_H \right) + A_H} \right)^{-\beta} \left(\frac{\beta \left(A_F + A_H \right) c}{(\beta - 1) \left(A_F + A_H \right) + A_H} - c \right) \geq$$
$$A_F \left(\frac{\beta c}{\beta - 1} \right)^{-\beta} \left(\frac{\beta c}{\beta - 1} - c \right) \qquad (1)$$

Denote by $\lambda = A_F / \left(A_H + A_F \right)$, then we can rewrite equation (1):

$$\left(\frac{\beta c}{(\beta - 1) + \lambda} \right)^{-\beta} \left(\frac{\beta c}{(\beta - 1) + \lambda} - c \right) \geq \lambda \left(\frac{\beta c}{\beta - 1} \right)^{-\beta} \left(\frac{\beta c}{\beta - 1} - c \right)$$

$$\left(\frac{1}{(\beta - 1) + \lambda} \right)^{-\beta} \left(\frac{\beta}{(\beta - 1) + \lambda} - 1 \right) \geq \lambda \left(\frac{1}{\beta - 1} \right)^{-\beta} \left(\frac{\beta}{\beta - 1} - 1 \right)$$

$$\left(\frac{(\beta - 1) + \lambda}{\beta - 1} \right)^{\beta - 1} \geq \frac{\lambda}{1 - \lambda}$$

Thus, when λ is significantly smaller from one, this can be achieved. This is reasonable when H is a sufficiently larger/richer country.

On the other hand, if the company has headquarters at F, the regulator sets prices so that consumer surplus is maximized, and thus, it sets the minimum price consistent with the firm selling in H. Thus, the problem with the firm headquartered at F is:

$$\max_p A_H \frac{p^{1-\beta}}{\beta - 1}$$
$$\text{subject to } \left(A_H p^{-\beta} + A_F p^{-\beta} \right) (p - c) \geq \pi_F^*$$

Notice that this program is such that the objective of the regulator is to set the minimal price consistent with the constraint, call it p^c

Put simply, we have a model that predicts that the price set by the regulator is weakly higher for the local multinational than for the foreign one. But as λ grows it reaches a point when the constraint becomes binding. This means that as the size of F grows with respect to H the price of the foreign multinational converges to that of the local multinational. Thus, suppose that countries which are more heavy regulators in practice are relatively small in size. This would imply that they cannot influence substantially the prices in favor of the local multinationals. Or at least, they cannot influence prices enough for this to show in a relevant relationship in the data. As we will see, this is indeed the case in our data.

3 Econometric specification

In the previous section we have shown that the equilibrium price for product i of firm f in market k and country j, p'_{ikj}, can be represented as a function of competitors' pricing strategies, quality variables and other factors, summarized in the function A^*_{ikj}. Taking this into account, we consider the following log-linear specification:

$$\log(p'_{ifkjt}) = \alpha + A^*_{ifkjt} + v_{ifkjt}$$

where t denotes time, and v denotes an error term, and α is a parameter. We further consider that

$$\log(A^*_{ifkjt}) = X'_{ifkjt}\beta + Z'_i\gamma + \eta_r + d_t$$

where X and Z are vectors of respectively time-variant and time-invariant variables that potentially affect equilibrium prices, and β and γ are the corresponding vectors of parameters. The term η_r represents a specific effect, where r is (depending on the specification) either $i, f,$ or, k, and d_t is a time specific factor. After replacing these expressions in the above equation we obtain:

$$\log(p'_{ifkjt}) = \alpha + X'_{ifkjt}\beta + Z'_i\gamma + \eta_r + d_t + v_{ifkjt} \tag{2}$$

Note that when $r = i$, the effect of Z_i is absorbed by the individual effects and, consequently, it is not directly identifiable. Since we have a genuine interest in some time-invariant factors, we follow a two-stage procedure to estimate them (Mundlak, 1978): we first estimate the above equation and obtain an estimate of η_i, say $\hat{\eta}_i$, and then, in a second stage, we regress $\hat{\eta}_i$ against the time invariant factors. That is we estimate the equation:

$$\hat{\eta}_i = Z'_i\gamma + \eta_f + \eta_k + u_i \tag{3}$$

where u_i is an error term and η_k and η_f control for market (or molecule) and firm specific effects, respectively. Depending on the exact assumption about them, we follow one estimation strategy or another. For example, in case we assume they are random and uncorrelated with the variables in Z, then an LS estimate of the above equation identifies the parameters of the model. Alternatively, we can follow a conditional approach and use an LSDV estimator controlling either η_k, η_f or both. We'll explore all these possibilities in data.

An alternative strategy to identify the effect of the Z variables is to assume that the product specific effects are well represented by the combination of market effects, say η_k (or, alternatively corporation effects, say η_f) and the $Z'_i\gamma$ component. Note that, in this particular case, the effect of the variables in Z can be identified in just one step.

We carry the analysis at two levels: country by country (25 countries) and pooling the data for all the countries. Since the number of markets and number of product varies across countries,

we check the robustness of the results to the variation in two complementary dimensions: the number of countries in which the corporation to which the product belongs is present (for example: 1+, 10+, 20+, 25), and the number of countries in which a given molecule is present (for example: 1+, 10+, 20+, 25). We also present results when restricting the sample to single molecules, and when restricting it to products for which the molecule and the corporation is present in all the countries of the sample.

Regarding the estimation methods, we estimate equations (2 and 3) using a Within Groups panel data method. In the first stage, we control for time-invariant heterogeneity across product, while in the second we control for this heterogeneity across molecules. In order to avoid potential endogeneity problems of some variables, we follow an IV approach and lag all the time-varying (potentially endogenous) covariates in the model.

4   Data, construction of the variables and specification

We use a multi-country and multi-product data set from the IMS MIDAS international database for the period 1998-2003[11]. This dataset encompasses a large number of countries including the top ten in terms of expenditure, as well as medium size and small countries (see Table 1 for a list of countries and summary statistics). It also includes a large number of groups or anatomic classifications, and allows to study the price variation across countries which differ in terms of both regulatory regimes and industrial structure. Many corporations supply drugs in several of these markets that can be defined at different levels of disaggregation. In the current study we regard the 4-digits Anatomic therapeutical classification (ATC4) as a market, but it would be desirable to contrast our results using alternative levels of disaggregation.[12] Table 2 presents the distribution of corporations depending on the number of markets supplied and Table 3 presents the distribution of molecule ages by countries.

4.1   Variables and first stage and second stage specifications

The dependent variable in our analysis , called *Price*, corresponds to sales revenue divided by the number of 'standard units' sold. Accordingly, when several formulations of the product co-exist in the market, this corresponds to a weighted average of the price per standard unit of all these alternative formulations. Nominal country specific quantities are converted to 2000 US $.

Marginal costs are almost irrelevant in this industry.[13] Accordingly, in our regression we use a hedonic approach and include quality and competition variables (see section A.1 of the

---

[11]Our data includes information from the 4th quarter of each year, except for 2003, for which the information is provided for the 2nd quarter.

[12]The ATC code was not provided in the original data supplied from IMS. Fortunately we obtained an additional sample from IMS Spain which helped us to recover the ATC for the rest of the countries. We managed to match practically all the records in sample.

[13]See, e.g. Berndt, Cockburn and Griliches, 1996, Suslow, 1996, Berndt, Pindyck and Azoulay, 1999, and Cockburn and Anis, 2001.

appendix for a list of variables with definitions) to proxy the equilibrium price. Our controls can be classified in one of two categories: time-variant and time-invariant controls.

Our list of time variant controls or *first stage* controls includes: the firm's size, *Fsize*, which is constructed as total corporation sales (excluding sales of the product under analysis) in each country. Firm's size is included in log form in order to give more weight two differences in small values than in large values and it is lagged one period in order to avoid endogeneity problems. The average global price of the molecule (excluding the product under consideration) or *Globalprice*. The variable *Ngen* is the number of generic products in each market and country. *New* is a dummy variable equal to one if the product was launched in the previous year and zero otherwise.

Among the competition variables we include the Hirschmand-Herfindähl concentration index of the local firms (excluding the firm the product belongs to), *HHI*. We also include the market share of the corporation *Mshare*, in the market and its square, since we would expect that higher sales lead to higher prices. In order to capture differential effects between local and foreign firms we interact these variables with the *local* and *local multinational* dummies (to be defined later). Again both variables could be regarded as endogenous and we lag them one period.

Finally, we construct several share variables: the market share of each variety in the market, *Mshare*, the market share of all the national products in the market, *Natshare*, and the *Berry index* which measures the degree of specialization of the corporation.

Our list of time invariant controls starts with the *Fquota*, defined as the average firm quota in the country. *Singlemol* takes a value of one, if the product consists of a single molecule, and zero otherwise. Molecule age, *Molage*, is the time elapsed since the molecule was launched to December 31, 2003. The age distribution of molecules and products is presented in Table 3. We also include to *Censormol*, which equals 1 if the product was launched before January 1, 1991 and zero otherwise; *Censorlag*, which equals one for products launched before January 1, 1991 and one otherwise. We also include *Summol* which counts the number of countries a given molecule is present. Therefore it can be interpreted as a proxy of diffusion of a molecule. We finally construct dummies controlling the type of firm: *local*, *local-multinational* and *multinational*, for respectively local-non multinational, local-multinational and non-local multinational firms. They are interacted with *Fquota*, *Mshare* as well as *New*.

Following Danzon and Furukawa (2003) suggestions, in the time variant pooled countries specification we control for differences between the countries with two variables: *FPC* or fraction of public consumption in GDP, and *GDPPCUSD* or GDP per capita in 2000 US $. Both of them are interacted with a set of regulatory dummies. We consider three levels of regulation (low, medium and high, respectively):[14] (I) Australia, Czech Republic, Canada, Denmark, Finland,

---

[14]See Table 1 for summary statistics for all the countries. The classification was done by sending the list of countries to three experts in health and pharmaceutical economics, prior to the statistical analysis of our data. We asked them for a classification of countries in the list in three groups. In the very few cases where the classification was not anonymous (no country was ever placed in three different categories), we ranked it according

Germany, Hungary, The Netherlands, Norway, Poland, Sweden, Switzerland, UK, and the US; (II) Austria, Belgium, France, Japan, Greece, Portugal, Spain; (III) Argentina, Brazil, Egypt, Italy, Portugal.[15]

For the regression analysis we use log transformations of *Price*, *Fsize*, *Globalprice Molage*, and *Summol* so we value more the differences in smaller than in larger values. In order to avoid potential simultaneity bias all the regressors are lagged one period except for those related to the age of the product, which by nature are predetermined (specially once we control for *New*).

5 Results and interpretation

In this section we present the results from the empirical analysis. We begin with a review of the country-by-country results and continue with the pooled results (for all products as well divided by anatomic therapeutical group).

5.1 Country by country results

In tables 4 to 6 we present the country-by-country results of the first (top panel in each table) and second stage (bottom panel) regressions for all the countries in sample. In all the first stage regressions we use a IV-FE estimator, and a standard LS estimator in all the second stage regressions. Likewise, in all cases we present results with the complete sample of products. [Detailed results with restricted subsamples –by either restricting the number of countries a given corporation (C dimension), or a given molecule (M dimension), is present– are available upon request.]

After controlling for product (and time) fixed effects, the explanatory power of time varying variables is very limited in practically all the countries, evidencing very little time-series variation in the data. Despite so, we still are able to identify some regularities across countries.

- Key findings in first stage country-specific regressions:

  1. Both the market share of national products in the market the product belongs to, the concentration of local products, and the Berry index seem to have little effect on prices.

  2. New products get a small premium in a number of countries. The largest premium is observed for the US (whose results are reported in the last column of table 6). The nationality of the product does not command a significant change on the premium for novel products with two notable exceptions: the case of Italy in which new products

to the majority view. The experts, whose help is gratefully acknowledged were:.Guillem López, Félix Lobo and Vicente Ortún.

[15]Note that our classification, for the top countries, in terms of expending, is similar to that employed in Danzon and Chao (2000a, 2000b).

12

from exclusively local producers get an extra premium and Canada where new product from local multinationals also get an important premium.

3. Other things equal, the effect of firm size in prices is either non-significant or negative but small. The largest effects are found in Denmark and the US.

4. The number of generics in the molecule, significantly reduces the level of prices in a large number of countries. In this case the larger effect are found in Italy and Japan. For the US the effect of the number of generics is insignificant.

5. Global prices have very little independent effect, with the notable exceptions of Germany, Spain and the US.

- Key findings in second stage country-specific regressions:

1. Other things equal, products from exclusively local corporations have lower prices in practically all the countries. The effect of being local multinational is less clear, since in a number of countries the effect is either insignificant or negative. Non-significant coefficients imply that local and foreign multinational are treated equally. This is the case of the US or Canada, among other countries. In fact, with the exception of France, in all countries with a significant pharmaceutical industry, both local and foreign multinational are treated equally. Apart of this, in a number of countries we find a significantly negative coefficient (France, Italy, and Sweden among other countries). However, in practically all cases the implicit coefficient lays in between of those for exclusively local corporations and foreign multinational firms. Thus large multinational conglomerates seem to receive a premium over small, local, producers.

2. With the exception of Poland, the effect of single molecule is either non-significant or positive, specially in big pharmaceutical markets (notably Canada, Germany, Italy, Netherlands, Spain, Sweden, UK and the US).

3. In a large majority of countries the coefficient of the *generic* variable is significantly negative, with the notable exception of Canada. The largest negative effects are observed in Belgium, France, Norway, Hungary and the UK.

4. Finally, our proxy for diffusion of a molecule, *summol*, affects positively product prices in a large number of countries (Austria, Belgium, Brazil, Canada, Czech Rep., Egypt, France, Germany, Greece, Hungary, Japan, Poland, Portugal, Spain, Sweden, UK and the US.

Let us now turn to pooled results, which are expected to be very informative since the variation in data augments drastically.

5.2 Pooled Results

In tables 7 and 8 we respectively present the result of the first and second stage regressions when pooling the information of all countries in sample. In both tables columns (1) and (2) present respectively the all-products and single molecule first stage and second stage results. The rest of the columns in the aforementioned tables present the results when varying the number of countries a corporation is present (dimension C) and the number of countries the molecule is present (dimension M).[16] The exploration of the results in these two dimensions will help us to, firstly, check the sensitivity of the results to the sample employed, and, secondly, to better understand the underlining common characteristics of the problem. As in the previous section, in all the first stage regression, we use a IV-FE estimator (with product fixed effects) with clustered standard errors. Alternatively, in all the second stage regression we use a LS-FE estimator (with molecule fixed effect).

We obtain a number of interesting results in the first stage regressions.

1. Neither the share of local product or the degree of concentration affect strongly (in a quantitative sense) the prices. In fact the effect of the share of local product is even negative when we restrict the sample to products of corporation presents in many countries. Regardless of the dimension explored, the effect of the firm size is significantly negative, but small. The degree of specialization of the corporation seems to have a positive effect on prices as we move along the C dimension, but this is not confirmed when we move in the M dimension. Apart from this, the number of generics does not seem to have any systematic effect on prices.

2. As expected, new products get a premium which increases in the two dimensions explored. Interestingly, we find that new product launches on the part of local innovative firms receive a larger premium than other types of (multinational) firms. As we shall illustrate in the next section (see table 9) the finding is robust to the analysis by therapeutical class.

3. The effect of the global price is always positive and significant. The effect decreases when the number of countries the corporation is present increases and increases with the diffusion of the molecule. It is also interesting to note that the absence of a global price (or global reference, which means the product is innovative) increases significantly the price (above 1/3 if we move in the C dimension, and above 1/2 if we move in the molecule dimension).

4. Finally, the pooling strategy allows us to identify the effect of some aggregate variables, such us the fraction of public expenditure in the GDP and the per capita GDP. After preliminary exploration of the date we interacted both variables with the level of regulation

---

[16]We present results when the sample is restricted to products which belong to corporation or molecules present in 1+ (all sample), 10+ or 25 countries. Results for other restricted samples are in line with the ones presented here and are available upon request.

(from 1, low, to 3, high). For low regulated countries (REG1), the effect of both variables is positive and significant and increases in the two dimensions studied. In particular, other things equal, an increase of one percentage basis points in the fraction of public expenditures in the GDP translates into a 1.2 and 2.0 percent increase in the price, depending on the specification. Note that the elasticity increases as we move in the C dimension and reduces with the M dimension. Likewise, the price elasticity of the GDP per capita is very high, between 2.0 and 0.8 depending on the specification. In contrast with the result for the fraction of public expenditure, the price elasticity of the GDP per capita reduces as we move in either the C or the M dimension. In medium and high regulated countries the effect of the fraction of public consumption in the GDP gets reduced significantly, except for those molecule that are present in all the countries. Alternatively, the effect of the GPD is significantly higher for both types of countries.

We now turn our attention to second stage regressions results.

1. Being a product from a exclusively-local corporation clearly reduces the price by approximately 15 per cent regardless of the dimension studied.

2. Alternatively, being a product from a local multinational has no clear effect on prices except for those product in which the corporation and the molecule is present in all countries (last column of Table 8). In this particular case the effect is sizeable and negative. Thus, in general local and international multinational corporations are treated equally.

3. We find that on average the price for generic products is between -0.15 and -0.20 percent lower than other prices. Again, the effect is larger when the sample is restricted to products of corporation and molecules present in all countries.

The analysis of country fixed effects, as reported in Table 8 and Figure 1 for selected cases, gives us a very interesting picture of the role of the regulation. First of all, price in developing countries (with the exception, in some cases, of Egypt) or very regulated (European) countries are lower than in less regulated countries, particularly lower than in the US. As we move to a more homogeneous sample in the C dimension the price gap is more evident. Alternatively, when we move in the M dimension (varying the number of countries a given molecule is present), the effect is less evident, even non-significant in some cases. The differences are more evident when we look to the last column of Table 8 (were the sample is restricted to products of corporations and molecules present in all countries, see also Figure 1): the average country effect for the very regulated countries is -4.80, for the regulated ones -3.20 and for the low regulated countries -0.435.

Within the group of less regulated countries (which includes the Northern, Eastern and some Central European countries plus Australia, Canada and the US) we can also document several interesting findings. Firstly, in the overall sample (or the sample of single molecules) there is

15

little evidence than average prices are higher in the US than in other countries (particularly the Eastern European ones, but also other countries), since we find a number of cases for which the country fixed effect is positive. Note that this finding is in accordance with the results in Danzon and Chao (2000b) but obtained in a much more general sample both in terms of products and countries considered. Secondly, as we move in the C dimension, all the country specific effects decrease, that is, those positive are closer to zero or change sign to negative (this is the case of Canada, Germany, Switzerland and UK) and those negative turn out more negative. Thirdly, when we move in the M dimension the initial picture remains basically unaltered. Thus, the US have a relatively lower price (compared to other developed countries) for products manufactured by multinationals, and a higher price with products that are "very common" (probably at a later stage in their life cycle). This is consistent with the explanation that the U.S., with her insistence in competition rather than regulation to contain prices, does well for goods where there can be competition (mostly off-patent not quite innovative goods). On the other hand, the other (mostly European) developed countries are successful at capping the prices of patented innovative goods, whereas they are less able to contain prices for products where competition could do a good job at restraining prices in the absence of regulation.

Apart of this it is interesting to note the case of the Nordic countries (Denmark, Finland, Norway and Sweden, which are classified in the group of "low" regulated countries), whose associated coefficients all over Table 8 are significantly more negative than the rest of the coefficients for the group of low regulated countries. This implies that Nordic countries manage to achieve lower prices without a stronger regulation, suggesting an interesting avenue for future research.

5.3 Pooled results by therapeutical class

In tables 9 and 10 we present the pooled sample results of the first and second stage regressions by therapeutical class.[17] We only present results when the sample is not restricted in any dimension. As a rule, the analysis by therapeutical class gives a very similar qualitative picture than the pooled analysis we have performed in the previous section.

In the first stage regressions we obtain the following results.

1. The effect of the share of national product is in general non-significant with some important exceptions: class C, for which it is negative, and classes L and M for which it is positive.

2. We confirm that once we control for product effects, the effect of the degree of concentration of national producers, the Berry index or firm size are not, as a rule, significant.

3. We also find that new products from exclusively local producers get a small premium for practically all therapeutical classes.

4. As found in previous studies the effect of the number of generics in the market is ambiguous since it is positive for classes A, N and R and negative for classes J and M.

---

[17]We have analyzed twelve classes: see variable definition for a list of classes.

Figure 1: Country effects for selected models.

note: The dashed line marks the US country effect's level.

5. The results of the country level variables (GDP per capita and Public expenditure to GDP ratio) are mostly in line with those reported in Table 7. The elasticity of the price to the size of the public sector ranges from 1.4 (class C) to 3.0 (class H) and the elasticity of the GDP per capita ranges from 0.62 (class H, non-significant) to 2.5 (class A). The effect of the size of the public sector reduces significantly as we move to more regulation. On the contrary, the effect of the GDP per capita either does not vary with the level of regulation or it increases mildly.

The second stage results by therapeutical class clearly confirm that products from exclusively local firms are, other things equal, cheaper than products from multinational corporations. In contrast, we do not detect differences in any therapeutical class between local and foreign multinationals. The results for the rest of the quality variables are, as a rule, in accordance with expectations.

Results for country fixed effect are also in line with those we discussed in the previous section. The estimated coefficients for very regulated countries are negative, which implies that regulation, other things equal, reduces average prices for practically all the anatomical therapeutical groups. What is more interesting is the fact that, for a large number of groups, the US is not, other things equal, the country with highest prices. In fact, average prices in Eastern (low regulated) European countries are, in a majority of groups, higher. More importantly, in some groups average prices in the UK, the nordic countries, Switzerland or, even Canada, are higher.

6   Conclusions

In this paper we have investigated empirically the determinants of prices for pharmaceuticals. We have used a more extensive database than most previous studies, and we have used a large number of controls and paid a close attention to the empirical strategy and specification.

The sensibility of our results in other domains has allowed us to tackle the thorny question of the determinants of regulation. We argued that an obvious footprint of rent-seeking regulation would be the existence of lower prices in countries without significant industrial presence. Our answer is robust, but contrary to conventional wisdom. In most countries, their own multinationals command no price premium with respect to foreign ones. Local, non-multinational firms tend to have lower prices than any multinational, and whether these multinationals are foreign or local does not affect prices in a statistically significant way.

Our results, thus, do not support the view that the outcome of regulation conforms with the short-sighted best interest of local consumers. We do have evidence, on the other hand, that quality matters for prices, that firms exercise considerable market power, and that *all* multinational corporations obtain a price advantage. We have constructed a theoretical model that accounts for all this findings simultaneously. The model is one of an imperfectly competitive

market. Demand is sensitive to quality, and firms, which can be purely local, or multinational, have their prices regulated by a government who cares only about the benefits of its voters. The explanation for the absence of a local price premium is that multinationality confers a protection against government intervention. Firms know that allowing prices to go too low in one country could lower prices in all others, say because of the existence of reference prices. They may prefer, thus, to exit completely one market rather than allowing it to spoil profits in all others. Knowing this, and since the product has indeed a value for voters, the regulator will refrain from driving too hard a bargain. Thus, there is a sense in which a reference price (or similar) policy in one country becomes a "commitment device" to avoid lowering price in another one. Its effects are akin to the low-price guarantees that have been widely studied in the industrial organization literature (Holt and Scheffman 1987, Arbatskaya, Hviid, Shaffer 2004) because of their anticompetitive implications.

Also, our results do not support the view that the U.S. has higher prices than the rest of the countries in the sample. This confirms and extends prior work of Danzon and Chao (2000b), and contradicts the assertions contained in the U.S. Department of Commerce report (2004). An interesting avenue for further research is to explain how some countries with low regulation (such as the Nordic countries) achieve significantly lower average prices than others.

In this paper we have thus argued that pharmaceutical prices do not show signs of being driven by pure rent-shifting motives from politicians. This does not mean that they are set in a way that maximizes welfare. Indeed, these prices have to balance the provision of long term incentives to innovation with the needs of present generations, something that is particularly difficult given the decentralized way in which regulations occur throughout the world. A necessary extension to the current work would be to ascertain empirically the relationship between current prices and socially efficient ones. This would, of course, require further theoretical work to determine a good benchmark (or a set of them) for socially efficient prices.

References

[1] Arbatskaya, M., M. Hviid and G. Shaffer (2004), "On the Incidence and Variety of Low-Price Guarantees," *Journal of Law and Economics*, 47:307-332.

[2] Ballance, R., J. Pogány and H. Forstner (1992), *The World's Pharmaceutical Industries*, London, UK: Edward Elgar.

[3] Berndt, E.R., Cockburn, I., and Griliches, Z, 1996, "Pharmaceutical innovations and market dynamics: Tracking effects on price indexes for antidepressant drugs", Brookings Papers on Economic Activity: Microeconomics, pp.133-188.

[4] Berndt, E.R., Pindyck, R.S. and Azoulay, P., 1999, "Network effects and diffusion in pharmaceutical markets: antiulcer drugs", NBER Working Paper Series 7024.

[5] Caves, R., Whinston, M., and Hurwitz, M. (1991) "Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry," Brookings Papers.

[6] Cockburn, I. and A. Anis (2001), "Hedonic Analysis of Arthritis Drugs," in E. Berndt and D. Cutler (eds.) *Medical Care Output and Productivity*, University of Chicago Press, Chicago.

[7] Danzon, P.M. and L.W. Chao (2000a), "Does Regulation Drive Out Competition in Pharmaceutical Markets," *Journal of Law and Economics*, 43:311-357.

[8] Danzon, P.M. and L.W. Chao (2000b), "Cross-national price differences for pharmaceuticals: how large, and why?", *Journal of Health Economics*, 19, 159-195.

[9] Danzon, P.M. and M Furukawa (2003), "Prices and availability of Pharmaceuticals: evidence from nine countries" *Health Affairs* 521–536.

[10] Danzon, P.M. and M Furukawa (2006), "Prices and availability of Pharmaceuticals: an International Comparison, *Health Affairs*, 25: 1353-1362.

[11] Domínguez, B., J.J. Ganuza and G. Llobet (2006), "R&D in the Pharmaceutical Industry: A World of Small Innovations," mimeo, CEMFI and Universitat Pompeu Fabra.

[12] Ekelund M. and B. Persson (2003), "Pharmaceutical Pricing in a Regulated Country," *The Review of Economics and Statistics*, 85:298-306.

[13] Frank RG and Salkever DS (1992) "Pricing, Patent loss and the market for pharmaceuticals", *Southern Economic Journal*, 59(2), 165-179.

[14] Frank RG and Salkever DS (1997) "Generic entry and the pricing of pharmaceuticals", *Journal of Economics and Management Strategy*, 6(1), 75-90.

[15] Gambardella, A., L. Orsenigo and F. Pammolli (2000), Global Competitiveness in Pharmaceuticals: A European Perspective, Report prepared for the Enterprise Directorate-General of the European Union.

[16] Grabowsky, H. and J. Vernon, (1992) "Brand Loyalty, Entry and Price Competition in Pharmaceuticals after the 1984 Drug Act", *Journal of Law and Economics*,35, 331-350.

[17] Holt, C.A. and D.T. Scheffman (1987), "Facilitating Practices: The Effects of Advance Notice and Best-Price Policies," *The RAND Journal of Economics*, 18:187-197.

[18] Kyle, M (2005), "Price controls and entry strategy", *Review of Economics and Statistics*, forthcoming.

[19] Lu, Z.J. and W.S. Comanor (1998), "Strategic Pricing of New Pharmaceuticals," *The Review of Economics and Statistics*, 80:108-118.

[20] Mundlak Y (1978), "On the Pooling of Time Series and Cross-Section Data", *Econometrica* 46, 69-85.

[21] Scherer, F.M. (2000), "The Pharmaceutical Industry," in A. Culyer and J. Newhouse, Eds. *Handbook of Health Economics*, Amsterdam: North Holland.

[22] Suslow VY (1996). "Measuring Quality Change in the Market for Anti-Ulcer Drugs," in RB Helms (ed.), *Competitive Strategies in the Pharmaceutical Industry*, Washington DC: AEI Press, 49-72.

[23] U.S. Department of Commerce (2004), "Pharmaceutical Price Controls in OECD Countries: Implications for U.S. Consumers, Pricing, Research and Development and Innovation," U.S. Department of Commerce, International Trade Administration, Washington D.C.

[24] Wiggins S.N. and Maness R. (1994), "Price Competition in Pharmaceutical markets", unpublished manuscript, Texas A&M University.

A   Variable definition and descriptive statistics

A.1   Variable definition

Variable	definition
Price	Sales revenue divided by the number of standard units sold (in logs)
Natshare	The market share of all national products in the ATC4 market
HHI-local	The Hirschmand-Herfindähl concentration index for national firms in the ATC4 market
fsize	Firm size (in logs)
new	A dummy taking one if the product was first observed in the previous year
Berry index	The Berry index measure the degree of specialization of the corporation
Ngen	Number of identified generics in the market
dum-GP n.a.	Dummy of absence of a global price of reference
global price	Average global price of the molecule in US real $
local	A dummy taking one if the corporation is local-non multinational
localmulti	A dummy taking one if the corporation is local but multinational
singlemol	A dummy taking one if the product is not composite
lsummol	Log of the number of market a molecule is present
generic	A dummy taking one if the product is generic
Mshare	Market share of each variety in the ATC4 market
Fquota	Average (in sample) firm quota of the firm in a given country
molage	Time elapsed since the molecule was launched to December 31, 2003.
censormol	A dummy taking one if the molecule was launched before January 1, 1991
censorlag	A dummy taking one if the product was launched before January 1, 1991
fpc	Fraction of public consumption in GDP (source: UN; in logs)
gdppcusd	GDP per capita in 2000 US $ (source: UN, in logs)
REG	Level of regulation: 1 low, 2 medium, 3 high.
	THERAPEUTICAL CLASSES
A	ALIMENTARY TRACT AND METABOLISM
B	BLOOD AND BLOOD FORMING ORGANS
C	CARDIOVASCULAR SYSTEM
D	DERMATOLOGICALS
G	GENITO URINARY SYSTEM AND SEX HORMONES
H	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSUL
J	ANTIINFECTIVES FOR SYSTEMIC USE
L	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
M	MUSCULO-SKELETAL SYSTEM
N	NERVOUS SYSTEM
R	RESPIRATORY SYSTEM
S	SENSORY ORGANS

Table 1: Summary statistics by country

country	# of corp	number of markets ATC4	number of markets mol	number of markets prod.	prod /mol	ATC4 HHI mean	ATC4 HHI med	Average prices (1)	Average prices (2)	Average prices (3)	GDP PC $	FPC	REG
Argentina	250	273	1143	2892	2.5	.237	.158	14.7	1.92	1.20	7666	.137	3
Brazil	250	263	966	2711	2.8	.254	.140	2.66	.762	.362	3503	.190	3
Egypt	238	263	1038	1965	1.9	.293	.196	.287	.196	.081	1467	.097	3
Italy	215	234	669	1821	2.7	.286	.203	5.48	.293	.220	18680	.182	3
Austria	207	234	716	1311	1.8	.402	.302	14.2	.607	.510	23503	.192	2
Belgium	183	200	508	962	1.9	.396	.297	4.63	.207	.174	22271	.211	2
France	214	235	721	1800	2.5	.268	.195	3.17	.143	.125	22065	.232	2
Greece	205	223	604	1216	2.0	.401	.329	9.83	.956	.588	10281	.157	2
Japan	181	213	530	1800	3.4	.354	.247	19.5	.523	.752	37361	.164	2
Portugal	172	187	446	875	2.0	.379	.286	1.20	.113	.069	10629	.205	2
Spain	220	225	640	1620	2.5	.296	.212	4.00	.290	.200	13785	.175	2
Australia	160	172	438	909	2.1	.397	.305	8.28	.407	.316	20315	.179	1
Canada	213	236	812	2397	3.0	.246	.153	5.66	.244	.203	23198	.185	1
CzechRepublic	239	264	803	1406	1.7	.406	.332	4.50	.830	.322	5426	.220	1
Denmark	197	222	653	1890	2.9	.235	.152	24.1	.812	.823	29730	.252	1
Finland	154	184	459	695	1.5	.451	.367	12.7	.551	.508	23161	.206	1
Germany	261	289	1489	5831	3.9	.169	.097	7.83	.344	.300	22730	.189	1
Hungary	188	205	550	891	1.6	.411	.333	5.47	1.17	.430	4661	.096	1
Nether	146	172	404	1084	2.7	.393	.287	7.29	.312	.267	23314	.226	1
Norway	140	164	388	664	1.7	.437	.336	12.4	.314	.352	39484	.191	1
Poland	221	239	678	1259	1.8	.412	.314	6.89	1.60	.694	4307	.189	1
Sweden	176	204	590	1431	2.4	.306	.226	28.8	1.06	1.17	27050	.265	1
Switz	228	252	828	1336	1.6	.360	.279	9.67	.281	.339	34330	.111	1
UK	189	209	585	1054	1.8	.426	.342	6.97	.284	.282	24525	.186	1
US	264	302	1397	5785	4.1	.194	.115	16.0	.468	.470	34262	.143	1

Notes: The sample is restricted to products with positive consumption in the 1998-2003.
(1): Average prices; (2) Av of prices relative to per capita GDP (in 2000 US $); (3) Price average relative to per capita GDP (in 2000 US $ but corrected for PPP). FPC: public consumption to GDP ratio; REG: Regulatory level: a lower number indicates less regulation.

Table 2: Distribution of the number of molecules of the corporations by country

country	1	2-4	5-9	10-14	15-20	21+	Total
Argentina	37	51	32	20	13	28	181
Australia	19	12	12	7	2	9	61
Austria	76	34	20	4	5	11	150
Belgium	19	32	21	7	2	8	89
Brazil	32	33	27	17	14	22	145
Canada	46	34	18	9	13	22	142
CzechRepublic	39	39	25	12	9	9	133
Denmark	37	25	16	8	5	13	104
Egypt	68	41	10	9	10	16	154
Finland	46	19	13	9	3	6	96
France	47	40	21	5	5	12	130
Germany	128	128	54	27	17	31	385
Greece	60	43	27	16	7	3	156
Hungary	26	29	14	8	4	7	88
Italy	59	73	37	18	5	9	201
Japan	28	40	41	16	8	5	138
Nether	17	26	14	7	1	13	78
Norway	36	20	14	7	5	5	87
Poland	57	37	24	11	10	6	145
Portugal	25	33	34	8	2	5	107
Spain	35	44	38	16	7	13	153
Sweden	44	38	15	9	6	12	124
Switz	57	40	23	9	6	8	143
UK	47	45	16	9	7	8	132
US	189	146	76	22	23	60	516

Table 3: Distribution of molecule age by country

country	1	1-2	3-4	4-7	7-10	11+	Total
Argentina	23	110	185	393	308	124	1,14
Australia	13	75	82	145	99	24	438
Austria	11	109	126	251	145	74	716
Belgium	18	97	117	154	84	38	508
Brazil	32	146	179	296	202	111	966
Canada	15	102	101	229	285	80	812
CzechRepublic	20	107	105	259	198	114	803
Denmark	15	81	93	230	168	66	653
Egypt	51	213	205	278	227	64	1,038
Finland	10	71	68	166	105	39	459
France	23	86	123	268	137	84	721
Germany	29	227	172	369	411	281	1,489
Greece	14	133	97	192	103	65	604
Hungary	9	93	90	184	122	52	550
Italy	12	77	129	248	138	65	669
Japan	4	82	106	151	136	51	530
Nether	11	62	66	128	92	45	404
Norway	6	73	84	132	67	26	388
Poland	10	76	127	172	220	73	678
Portugal	14	77	80	139	89	47	446
Spain	19	104	110	215	124	68	640
Sweden	6	80	128	209	125	42	590
Switz	4	98	141	276	229	80	828
UK	16	87	98	201	127	56	585
US	13	171	205	391	360	257	1,397

Table 4: Single country results (I): Argentina-Egypt. All products.

	arg	aus	aut	bel	bra	can	cze	den	egy
	1st stage price equation results including product fixed effects								
Natshare	-0.099	-0.065	-0.005	0.005	0.042	0.045	-0.002	0.031	0.049
HHI-local	-0.013	-0.007	-0.003	0.028*	-0.049	0.004	-0.049*	-0.012	0.038
fsize1	-0.001	-0.009	-0.004	0.004	-0.015	-0.011	-0.006	-0.040**	-0.012**
new1	-0.004	-0.003	0.009	0.024**	0.030*	-0.009	0.033*	0.014	-0.004
new1*local	0.100	0.008	-0.001	0.103**	-0.058	-0.018	-0.064	0.212*	0.006
new1*localm	0.013	0.003	-0.003	0.018*	-0.008	0.002	-0.027	0.034	-0.005
Berry index	0.071**	0.097*	-0.005	-0.012	-0.004	0.036	-0.042	-0.055	0.022
Ngen	0.027	0.010	-0.013	-0.033	—	0.116**	-0.014	-0.020	—
dum-GP n.a.	-0.012**	-0.012	-0.013**	-0.009**	-0.012**	0.004	0.002	-0.019**	0.005
global price	0.005	0.003	0.007	-0.025*	-0.007	-0.011	-0.019	0.028	-0.012
intercept	4.368**	3.997**	3.917**	3.602**	3.628**	3.181**	3.704**	4.303**	1.357**
N	8158	2534	3784	2839	7288	7296	3752	4868	6001
r2-w	0.894	0.290	0.288	0.341	0.761	0.051	0.195	0.177	0.913
r2-b	0.156	0.049	0.013	0.204	0.005	0.025	0.175	0.180	0.008
r2-o	0.138	0.021	0.003	0.105	0.021	0.005	0.082	0.129	0.035
F	729.78	275.59	128.28	98.25	569.13	12.26	120.07	179.83	1853.07
	2nd stage regression of the 1st stage average residual								
local	-0.454**	-0.904**	-1.045**	-0.991**	-0.580**	-0.591**	-0.825**	-0.957**	-1.089**
localmulti	-0.330	-0.935*	-1.149**	-0.305	—	-0.248	-0.040	-0.633**	—
singlemol	-0.010	-0.017	0.069	-0.062	0.007	0.382**	0.254	0.004	0.271*
lsummol	0.268**	-0.039	0.621**	0.568**	0.343**	0.531**	0.272**	0.053	0.211**
generic	0.111	0.129	-0.483**	-1.052**	-0.364**	0.402**	-0.419*	-0.326	-0.078
intercept	-0.972	2.389*	3.234**	2.591**	1.838**	11.147**	4.625**	3.486**	3.440**
N	2180	768	1065	857	2342	2045	1027	1409	1759
r2	0.068	0.045	0.165	0.204	0.093	0.177	0.058	0.054	0.157
F	11.31	2.51	14.86	15.42	21.79	31.26	4.42	6.61	29.48

notes: **,* significant at 1% and 5% respectively.
Clustered standard errors by corporation.
All regressors except those related to age are lagged one period.
1st stage omitted regressors: (MSHARE,MSHARE^2) * (local, localmulti, multinational) + time dummies
2sn stage omitted regressors: (FQUOTA, FQUOTA^2) * (local, localmulti, multinational)+
2sn stage omitted regressors: CENSORLAG, CENSORMOL)

Table 5: Single country results (II): Finland-The Netherlands. All products

	fin	fra	ger	gre	hun	ita	jap	Net
1st stage price equation results including product fixed effects								
Natshare	-0.072	-0.053	0.008	0.007	-0.175**	0.052	-0.037	0.016
HHI-local	0.006	-0.005	0.016	0.013	0.053	0.023	-0.008	0.010
fsize1	0.001	-0.008	-0.002	0.007	-0.007	-0.005	-0.005	-0.010*
new1	0.022	0.010	0.016**	0.014	0.012	0.015	0.015	0.003
new1*local	0.122	0.117	0.090*	-0.048	-0.136	0.091	-0.050	0.068
new1*localm	0.027	0.016	0.024**	-0.005	-0.028	0.013	0.010	0.010
Berry index	-0.016	0.037	0.002	0.015	-0.033	0.060**	0.096	0.131
Ngen	—	-0.002	0.004	-0.011	—	0.002	-0.012	-0.058*
dum-GP n.a.	-0.009*	-0.001	-0.003**	0.005	-0.031	-0.030**	-0.041**	-0.009*
global price	0.031	0.003	-0.003	0.047	0.006	-0.007	0.028*	0.015
intercept	4.146**	3.141**	3.300**	4.062**	3.645**	3.891**	4.117**	4.579**
N	1969	5798	17336	3741	2676	5759	5340	2615
r2-w	0.308	0.340	0.217	0.599	0.295	0.347	0.287	0.596
r2-b	0.353	0.313	0.313	0.000	0.088	0.013	0.048	0.042
r2-o	0.164	0.150	0.183	0.001	0.022	0.019	0.048	0.028
F	96.68	218.84	329.86	573.90	261.79	91.30	77.05	373.06
2nd stage regression of the 1st stage average residual								
local	-0.261	-0.685**	-0.046	-1.031**	-0.377	-0.446**	-1.038**	-0.028
localmulti	—	-0.393**	-0.113	-0.532	—	-0.413*	0.011	0.291
singlemol	-0.021	-0.145	0.246**	0.728**	-0.090	0.684**	-0.295	0.531**
lsummol	-0.030	0.532**	0.548**	0.464**	0.592**	0.053	0.317**	0.182
generic	-0.834**	-0.908**	-0.689**	-0.282	-1.132**	-0.388**	-0.252	-0.407*
intercept	-0.259	4.586**	6.958**	3.742**	4.650**	1.230	4.933**	3.964**
N	530	1654	4956	1066	686	1680	1509	858
r2	0.050	0.200	0.157	0.136	0.113	0.046	0.103	0.048
F	2.49	29.33	65.88	11.83	7.80	5.73	12.23	3.01

notes: **,* significant at 1% and 5% respectively.

Clustered standard errors by corporation.

All regressors except those related to age are lagged one period.

1st stage omitted regressors: (MSHARE,MSHARE^2) * (local, localmulti, multinational) + time dummies

2sn stage omitted regressors: (FQUOTA, FQUOTA^2) * (local, localmulti, multinational)+

2sn stage omitted regressors: CENSORLAG, CENSORMOL)

Table 6: Single country results (III): Norway-US. All products

	nor	pol	por	spa	swe	swi	uk	us
			1st stage price equation results including product fixed effects					
Natshare	-0.077	-0.072	-0.004	0.054	0.062	0.008	0.033	0.047
HHI-local	-0.056**	0.008	0.023*	0.037	0.015	0.012	0.023	0.048
fsize1	0.011	-0.000	0.006	0.005	0.005	0.002	-0.010	-0.022**
new1	-0.016	0.028*	0.010	0.018*	0.001	0.009	0.010	0.085**
new1*local	0.016	0.117	-0.004	0.129*	0.104	0.000	0.072	0.204**
new1*localm	-0.001	0.025	-0.009	0.023**	0.018	-0.001	0.005	0.041**
Berry index	—	-0.031	-0.011	-0.017	0.005	-0.035	-0.011	0.021
Ngen	-0.003	0.005	-0.029*	-0.017	0.002	-0.023	-0.026	-0.041
dum-GP n.a.	-0.004	-0.005	-0.005	-0.005**	-0.015**	-0.007	-0.006	-0.003
global price	0.006	-0.008	-0.017	0.003	0.037	-0.013	0.046**	0.007
intercept	4.623**	3.477**	3.801**	3.461**	4.574**	3.440**	4.172**	3.307**
N	1631	3643	2619	5074	3840	4410	3072	15474
r2-w	0.383	0.041	0.654	0.373	0.281	0.569	0.159	0.045
r2-b	0.000	0.428	0.014	0.127	0.149	0.010	0.031	0.243
r2-o	0.002	0.374	0.000	0.079	0.084	0.006	0.029	0.226
F	159.11	10.74	663.01	253.57	124.38	323.45	21.62	5.77
			2nd stage regression of the 1st stage average residual					
local	0.683	-0.645**	-0.009	-0.541**	-0.901**	-1.102**	-1.012**	-0.930**
localmulti	0.063	-0.839*	0.898*	0.100	-1.208**	-0.173	-0.073	0.160
singlemol	0.386	-0.513**	-0.124	0.280*	0.409*	-0.086	0.439*	0.502**
lsummol	-0.430	0.230*	0.548**	0.359**	0.040	0.612**	0.285**	0.176**
generic	-1.147**	-0.800**	-0.545**	-0.382**	-0.437*	-0.349*	-0.999**	-0.524**
intercept	6.322**	1.632	0.906	4.683**	5.537**	4.665**	3.958**	9.178**
N	476	979	755	1475	1118	1159	867	4626
r2	0.106	0.079	0.095	0.105	0.060	0.179	0.139	0.179
F	3.89	5.87	5.57	12.19	5.92	17.85	9.83	71.80

notes: **,* significant at 1% and 5% respectively.

Clustered standard errors by corporation.

All regressors except those related to age are lagged one period.

1st stage omitted regressors: (MSHARE,MSHARE^2) * (local, localmulti, multinational) + time dummies

2sn stage omitted regressors: (FQUOTA, FQUOTA^2) * (local, localmulti, multinational)+

2sn stage omitted regressors: CENSORLAG, CENSORMOL)

Table 7: Pooled countries results. 1st stage price equation. Product fixed effects

| | ALL | | SINGLE MOL | | Varying the # of countries a corporation is present | | | | Varying the # of countries a molecule is present | | | | C+M 25C | |
| | | | | | CORP 10C | | CORP 25C | | MOL 10C | | MOL 25C | | | |
	coef	t-stat	coef	t-stat	coef	t-stat	coef	t-stat	coef	t-stat	coef	t-stat	coef	t-stat
Natshare	0.001	0.04	0.010	0.59	-0.042	-2.10	-0.068	-2.67	0.002	0.08	0.120	1.89	-0.001	-0.02
HHI-local	0.007	1.04	0.006	0.86	0.004	0.59	0.001	0.16	0.007	0.96	0.003	0.11	-0.003	-0.10
fsize1	-0.013	-4.92	-0.013	-4.81	-0.012	-3.68	-0.011	-2.48	-0.013	-4.54	-0.014	-1.52	-0.016	-0.98
new1	0.005	0.91	0.006	0.94	0.027	5.70	0.029	5.11	0.008	1.35	0.025	2.14	0.051	3.48
dum-GP n.a.	0.430	17.07	0.444	16.51	0.321	10.69	0.368	9.33	0.482	15.65	0.790	5.99	0.588	4.32
global price	0.096	17.28	0.094	16.56	0.063	10.17	0.070	9.00	0.101	15.54	0.237	7.44	0.181	5.05
localnew1	0.121	10.14	0.116	9.24	–		–		0.116	9.02	0.117	4.13	–	
localnewm1	-0.029	-1.95	-0.027	-1.70	-0.045	-3.60	-0.054	-2.97	-0.028	-1.97	-0.064	-2.31	-0.108	-4.32
Ngen	0.001	0.91	0.000	0.52	-0.000	-0.45	-0.000	-0.28	0.000	0.57	-0.003	-1.36	-0.000	-0.09
Berry index	0.006	1.56	0.007	1.77	0.009	2.06	0.012	2.15	0.003	0.60	0.018	1.29	0.018	0.93
fpc	2.004	11.23	1.831	10.28	1.412	7.18	1.825	6.93	1.835	10.57	1.229	4.12	1.345	3.52
gdppcusd	2.008	9.42	2.000	9.40	1.034	4.14	1.078	3.28	1.861	8.85	1.427	4.47	0.808	1.93
fpc*reg2	-0.953	-3.88	-0.921	-3.50	-0.443	-1.59	-0.672	-1.70	-0.693	-2.88	0.197	0.45	-0.159	-0.33
fpc*reg3	-1.567	-4.68	-1.382	-4.05	-0.112	-0.19	-0.944	-1.37	-1.217	-3.53	-0.126	-0.26	-0.745	-0.96
gdp*reg2	0.407	2.68	0.367	2.39	0.396	2.43	0.562	2.66	0.424	2.68	0.755	2.44	0.839	2.06
gdp*reg3	1.085	4.48	1.159	4.70	1.714	5.61	1.654	4.21	1.289	5.27	2.025	4.92	2.422	4.45
intercept	-0.273	-0.54	-0.385	-0.76	2.418	3.66	2.828	3.48	0.187	0.37	-0.072	-0.09	1.927	1.82
N	131517		106892		68920		43645		93014		9891		4766	
r2-w	0.287		0.279		0.285		0.290		0.299		0.367		0.329	
r2-b	0.042		0.038		0.012		0.006		0.035		0.074		0.007	
r2-o	0.044		0.041		0.015		0.006		0.038		0.078		0.008	
F	237.06		195.13		121.37		84.08		182.84		55.86		39.70	

t-statistics obtained from clustered (Corporation x Country) standard errors. All regressors except those related to age are lagged one period.
1st stage omitted regressors: (MSHARE,MSHARE^2) * (local, localmulti, multinational) + time dummies

Table 8: Pooled countries results. 2nd stage regression of the 1st stage average residual. Molecule fixed effects

| | ALL | | SINGLE MOL | | Varying the # of countries a corporation is present | | | | Varying the # of countries a molecule is present | | | | C+M 25C | |
| | | | | | CORP 10C | | CORP 25C | | MOL 10C | | MOL 25C | | | |
	coef	t-stat	coef	t-stat	coef	t-stat	coef	t-stat	coef	t-stat	coef	t-stat	coef	t-stat
local	-0.163	-9.33	-0.163	-8.52	–		–		-0.146	-6.83	-0.182	-5.89	–	
localmulti	0.045	1.84	0.039	1.48	0.060	1.87	0.004	0.08	0.058	1.96	-0.123	-1.97	-0.274	-2.19
molage	-0.103	-4.13	-0.111	-4.11	-0.054	-1.97	-0.056	-1.79	-0.080	-2.84	-0.190	-2.08	-0.020	-0.34
lsummol	-0.038	-0.41	-0.026	-0.25	-0.064	-0.28	0.079	0.47	0.207	0.43	–		–	
censormol	-0.056	-0.84	-0.043	-0.62	-0.061	-0.71	-0.074	-0.59	-0.055	-0.72	0.374	2.54	0.006	0.03
censorlag	0.049	0.78	0.064	0.95	0.064	0.71	0.107	0.78	0.014	0.20	-0.275	-0.93	-0.019	-0.10
generic	-0.173	-5.91	-0.175	-6.11	-0.189	-4.48	-0.165	-2.81	-0.164	-5.09	-0.211	-2.23	-0.323	-4.37
arg	-1.957	-23.96	-1.777	-20.74	-2.144	-26.79	-3.747	-46.63	-1.949	-20.92	-2.085	-9.33	-5.097	-25.29
bra	-0.266	-3.16	-0.040	-0.45	-1.013	-14.43	-2.426	-33.72	-0.260	-2.93	-0.443	-2.51	-3.686	-25.14
egy	0.889	7.02	1.196	8.82	0.422	4.12	-1.280	-12.48	1.109	7.83	1.864	7.74	-1.571	-6.14
ita	-5.193	-61.26	-5.067	-56.71	-5.431	-81.83	-6.947	-105.13	-5.250	-56.35	-5.657	-27.63	-8.855	-70.88
aut	-2.840	-42.23	-2.602	-37.58	-2.530	-38.80	-3.704	-55.51	-2.456	-33.16	-2.087	-8.35	-3.578	-17.33
bel	-2.834	-37.32	-2.597	-32.38	-2.535	-37.01	-3.693	-51.75	-2.483	-29.41	-1.888	-8.02	-3.377	-15.60
fra	-3.043	-41.31	-2.807	-36.84	-2.723	-37.83	-3.862	-49.24	-2.700	-33.04	-2.149	-9.29	-3.716	-19.93
gre	-0.952	-11.07	-0.816	-9.56	-1.450	-21.08	-2.363	-33.72	-0.661	-6.85	-0.392	-1.25	-2.269	-15.22
jap	-3.530	-34.44	-3.323	-32.60	-2.709	-27.22	-3.883	-35.80	-3.032	-26.07	-2.227	-4.76	-3.639	-14.25
por	-1.040	-12.99	-0.858	-10.19	-1.564	-21.58	-2.577	-33.68	-0.790	-9.02	-0.448	-1.82	-2.412	-11.21
spa	-1.686	-20.67	-1.500	-17.61	-1.904	-25.42	-2.939	-36.89	-1.376	-15.15	-0.952	-3.29	-2.990	-23.01
aus	0.195	2.44	0.229	2.73	-0.461	-6.26	-0.687	-9.51	0.177	1.98	-0.027	-0.09	-0.695	-3.64
can	0.084	1.47	0.146	2.56	-0.302	-4.92	-0.545	-8.09	0.085	1.23	0.362	1.66	-0.440	-2.87
cze	2.124	27.54	2.153	27.66	0.380	5.24	0.240	3.01	1.932	22.85	1.569	6.97	0.326	1.88
den	-1.117	-16.20	-1.027	-14.02	-1.218	-14.68	-1.588	-20.25	-1.027	-13.59	-0.639	-3.32	-1.281	-9.19
fin	-0.181	-2.55	-0.144	-1.91	-0.657	-9.44	-0.951	-12.48	-0.180	-2.28	-0.034	-0.15	-0.762	-5.12
ger	0.202	3.10	0.249	3.64	-0.419	-6.52	-0.600	-8.84	0.189	2.61	0.155	0.97	-0.701	-5.36
hun	3.950	54.96	3.876	50.85	1.509	22.67	1.672	23.62	3.609	45.27	2.591	13.87	1.263	7.59
hol	-0.290	-4.05	-0.199	-2.67	-0.774	-11.63	-1.139	-16.84	-0.271	-3.41	-0.064	-0.27	-0.842	-3.81
nor	-1.103	-15.51	-1.038	-13.89	-1.087	-15.42	-1.424	-19.40	-1.018	-13.03	-0.606	-2.66	-0.902	-4.29
pol	3.043	41.31	3.015	39.89	0.998	14.36	0.911	11.53	2.781	34.24	1.935	6.48	0.612	2.42
swe	-0.916	-13.81	-0.811	-11.71	-1.068	-16.55	-1.512	-21.65	-0.839	-11.42	-0.515	-2.69	-1.291	-9.05
swi	0.208	2.43	0.157	1.73	-0.277	-3.66	-0.311	-4.08	0.172	1.82	0.172	0.60	-0.238	-1.99
uk	0.107	1.42	0.173	2.13	-0.401	-5.51	-0.703	-10.05	0.111	1.34	0.349	1.94	-0.435	-3.43
intercept	1.655	5.53	1.609	4.63	1.725	2.62	1.997	3.97	0.703	0.48	2.156	2.40	2.074	4.06
N	37846		30846		18756		11438		26938		2736		1154	
r2-w	0.787		0.773		0.754		0.851		0.782		0.811		0.878	
r2-b	0.320		0.237		0.199		0.359		0.109		0.395		0.386	
r2-o	0.471		0.466		0.344		0.467		0.469		0.672		0.742	
F	2851.0		2127.2		1627.9		2403.7		1971.9		7742.2		14764.7	

t-statistics obtained from clustered (Market) standard errors. All regressors except those related to age are lagged one period.

2nd stage omitted regressors: (FQUOTA, FQUOTA^2) * (local, localmulti, multinational). Omitted country: US.

Table 9: Pooled countries results by therapeutical class. 1st stage price equation. Product fixed effects. All products

	A	B	C	D	G	Therapeutical class H	J	L	M	N	R	S
	coef.	coef.	coef.	coef.	coef.	coef.	coef.	coef.	coef.	coef.	coef.	coef.
	coef.	coef.	coef.	coef.	coef.	coef.	coef.	coef.	coef.	coef.	coef.	coef.
Natshare	0.010	-0.217	-0.148**	0.107**	-0.074	-0.065	-0.033	0.176**	0.221**	-0.006	-0.028	0.075
HHI-local	-0.029	0.163*	0.016	-0.026	0.032	0.026	0.001	-0.012	-0.038	0.042**	-0.000	0.014
fsize1	-0.016**	0.009	-0.013*	-0.006	-0.005	-0.023	-0.008	-0.008	-0.013*	-0.011	-0.019**	-0.013
new1	0.005	0.040	0.020*	-0.008	0.021	-0.021	-0.006	0.010	0.017	0.005	0.003	-0.002
dum-GP n.a.	0.504**	0.104	0.622**	0.387**	0.818**	0.284*	0.676**	0.157	0.316**	0.604**	0.295**	0.286**
global price	0.155**	0.011	0.188**	0.117**	0.178**	0.038*	0.110**	0.017	0.077**	0.135**	0.112**	0.087**
localnew1	0.084**	0.113	0.119**	0.115**	0.102**	0.005	0.156**	0.134**	0.105**	0.109**	0.128**	0.125**
localnewm1	-0.054*	-0.091	-0.039	-0.036	-0.063**	0.020	-0.027	-0.025	-0.007	0.018	-0.006	-0.002
Ngen	0.005**	0.007	0.001	0.000	0.001	0.011	-0.018**	0.002	-0.015**	0.003**	0.004*	-0.005
Berry index	0.006	0.048	0.013	0.019	-0.009	-0.061	0.009	0.001	0.013	0.013	-0.018	0.019
fpc	2.108**	1.644*	1.408**	1.887**	2.336**	2.992**	2.276**	1.558**	1.921**	1.343**	1.778**	1.999**
gdppcusd	2.519**	1.063	1.486**	2.008**	1.455**	0.626	1.790**	1.138*	2.281**	1.226**	2.114**	2.004**
fpc*reg2	-0.806*	-2.519**	-0.906*	-1.146**	-2.049**	-3.917**	-0.309	-0.698	-1.180*	-0.427	-0.566	-0.463
fpc*reg3	-2.382**	-2.667**	-1.071*	-0.943*	-1.406**	-1.502	-1.592**	-0.017	-1.561*	-0.432	-1.467**	-1.334*
gdp*reg2	0.265	-0.906	0.470*	0.946*	0.739**	-0.039	0.564	0.864	0.412	0.693**	0.166	0.377
gdp*reg3	0.839*	3.073**	2.051**	0.625	2.030**	2.153*	1.442**	0.414	0.268	1.955**	1.278**	0.833
intercept	-2.210**	2.755	-0.622	-1.092	1.067	5.790**	2.192**	5.733**	-1.306	0.951	-1.573	-0.945
N	24709	2091	17649	10675	11512	1779	11341	4889	6224	15843	14498	9615
r2-w	0.309	0.156	0.336	0.335	0.399	0.238	0.381	0.163	0.247	0.309	0.258	0.294
r2-b	0.072	0.008	0.051	0.067	0.020	0.036	0.027	0.001	0.019	0.020	0.080	0.042
r2-o	0.069	0.006	0.075	0.066	0.021	0.037	0.039	0.005	0.017	0.027	0.075	0.043
F	126.7	13.6	115.9	48.9	73.5	9.6	87.9	18.3	46.7	101.4	98.1	58.9

notes:

notes: **,* significant at 1% and 5% respectively. Clustered (Corp. x Country) s.e. All regressors except those related to product age
are lagged one period. 1st stage omitted regressors: (MSHARE,MSHARE^2) * (local, localmulti, multinational) + time dummies

Table 10: Pooled countries results by Therapeutical Class. 2nd stage regression of the 1st stage average residual. Molecule fixed effects. All products

						Therapeutical class						
	A	B	C	D	G	H	J	L	M	N	R	S
	coef.	coef.	coef.	coef.	coef.	coef.	coef.	coef.	coef.	coef.	coef.	coef.
local	-0.194**	-0.331*	-0.126**	-0.239**	-0.243**	0.024	-0.154**	-0.131	-0.122	-0.100**	-0.123*	-0.046
localmulti	0.052	-0.122	0.050	-0.090	-0.002	-0.216	0.008	-0.061	-0.029	0.015	0.114	0.212
molage	-0.169**	-0.221	-0.037	-0.404**	-0.049	-0.364	-0.069	-0.048	-0.169**	0.010	-0.144*	-0.103
lsummol	-0.248	—	-1.137**	0.951	0.144	—	0.079	—	-0.169	0.272**	-0.110	0.140**
censormol	-0.176**	-2.555**	-0.201	-0.028	0.096	1.174**	-0.104	-0.221	-0.207	-0.093	-0.045	0.332
censorlag	0.086	2.504*	0.176	0.141	-0.086	-1.040**	0.014	-0.011	0.068	-0.029	0.051	-0.059
generic	-0.172**	0.318	-0.268**	-0.116	0.024	-0.208	0.010	-0.330**	-0.199**	-0.175*	-0.407**	-0.146
arg	-1.837**	-11.957**	-3.978**	0.115	-4.351**	-5.719**	-3.400**	0.799**	-0.464	-2.927**	-1.818**	-1.104**
bra	0.404*	-7.303**	-1.844**	1.053**	-2.511**	-4.397**	-1.486**	0.791**	1.099**	-1.252**	0.046	0.151
egy	1.604**	-6.745**	-0.018	1.935**	-0.745**	-4.802**	-0.311	1.038**	1.230**	0.258	1.121**	1.170**
ita	-4.939**	-14.374**	-7.517**	-2.661**	-8.228**	-9.644**	-6.920**	-1.728**	-3.118**	-6.343**	-5.185**	-4.240**
aut	-1.541**	-2.699**	-3.075**	-4.807**	-6.187**	-7.016**	-2.672**	-4.204**	-3.475**	-3.151**	-1.257**	-2.205**
bel	-1.603**	-2.272**	-2.930**	-4.907**	-5.884**	-7.155**	-2.895**	-4.365**	-3.379**	-3.279**	-1.208**	-2.069**
fra	-1.740**	-2.047**	-3.116**	-5.129**	-6.358**	-6.904**	-3.182**	-4.296**	-3.637**	-3.452**	-1.461**	-2.093**
gre	0.813**	-2.857**	-1.488**	-2.796**	-4.681**	-7.296**	-0.682**	-2.905**	-1.677**	-1.665**	0.492	-0.069
jap	-2.459**	-2.027**	-3.478**	-5.605**	-6.810**	-7.252**	-3.624**	-5.066**	-4.631**	-3.454**	-1.524**	-2.926**
por	0.573**	-2.531**	-1.556**	-2.575**	-4.517**	-7.228**	-1.059**	-2.758**	-1.702**	-1.809**	0.329	-0.067
spa	-0.225	-3.129**	-2.071**	-3.478**	-5.091**	-7.582**	-1.649**	-3.492**	-2.349**	-2.301**	-0.075	-0.881*
aus	0.753**	-0.622	-0.011	0.423	-0.238	-1.989**	-0.284*	-0.299	-0.156	-0.107	0.486**	-0.147
can	0.122*	-0.668	0.183	0.314	-0.101	-0.616	-0.370**	-0.253	0.035	0.062	0.430*	0.184
cze	3.457**	-0.204	1.233**	2.100**	1.162**	-0.588	1.201**	0.504*	2.514**	0.978**	2.667**	1.784**
den	-0.799**	-1.451*	-0.794**	-0.798**	-1.482**	-2.088**	-1.580**	-1.143**	-1.441**	-1.072**	-0.984**	-1.185**
fin	0.255*	-0.859	-0.272	0.063	-0.592*	-1.020*	-0.553**	-0.601**	-0.604**	-0.471**	0.122	-0.216
ger	0.786**	-0.713	-0.105	0.170	-0.268	-0.794*	-0.022	-0.271	-0.065	-0.104	0.250	0.383
hun	5.488**	1.343*	2.532**	3.923**	2.911**	1.421**	3.245**	2.067**	4.321**	2.130**	4.199**	3.764**
hol	0.316	-1.013	-0.201	-0.325	-0.854**	-1.211*	-0.706**	-0.813**	-0.430	-0.435**	-0.130	-0.562*
nor	-0.920**	-1.375*	-0.814**	-1.307**	-1.180**	-1.745**	-1.368**	-1.154**	-1.609**	-0.865**	-0.870**	-1.187**
pol	4.550**	0.095	1.850**	3.023**	1.969**	-0.050	2.157**	0.783*	3.444**	1.483**	3.511**	2.899**
swe	-0.582**	-1.340	-0.625**	-0.540*	-1.389**	-2.688**	-1.377**	-1.103**	-1.143**	-0.942**	-0.684**	-0.802**
swi	0.722**	-1.590	0.090	-0.527	0.189	0.406	0.001	-0.335**	-0.087	-0.161	0.596*	-0.005
uk	0.517**	-1.254*	0.109	0.332	-0.402	-1.121**	-0.594**	-0.398**	-0.004	-0.156	0.405*	0.187
intercept	1.937**	5.029**	4.495**	2.135	2.150**	6.261**	1.692*	1.300	2.765**	0.301	1.618*	0.946
N	7160	625	5079	3056	3164	486	3354	1333	1773	4627	4234	2763
r2-w	0.797	0.939	0.903	0.746	0.902	0.916	0.890	0.829	0.871	0.816	0.703	0.623
r2-b	0.440	0.677	0.208	0.651	0.617	0.341	0.484	0.193	0.253	0.524	0.418	0.366
r2-o	0.559	0.744	0.652	0.624	0.749	0.468	0.634	0.355	0.605	0.594	0.522	0.488
F	2903.8	3218.8	8.5e6	10735.3	1.9e6	724.9	8.4e6	1602.2	2763.6	1.4e6	134800	1.9e6

notes: **,* significant at 1% and 5% respectively. Clustered (Market) s.e. All regressors except those related to product age are lagged one period.
2nd stage omitted regressors: (FQUOTA, FQUOTA^2) * (local, localmulti, multinational). Omitted Country: US.